Parabilis Medicines (Ticker: PBLS US) is an American clinical-stage biotechnology company developing engineered peptide therapies for cancer. The company is domiciled in the United States and uses its proprietary Helicon platform to produce helical peptides designed to modulate intracellular protein interactions that are not accessible to small-molecule therapies or biologic drugs.

Parabilis plans to list on NASDAQ on June 10, 2026. According to published terms, the company plans to offer 25.0 million shares at a price range of $17.00 to $19.00 per share, raising approximately $450 million at the $18.00 midpoint. The estimated market capitalization is around $2.6 billion.

The company’s lead drug candidate, zolucatetide, targets the Wnt/β-catenin pathway, which is associated with a broad range of solid tumors. Parabilis is evaluating zolucatetide in ongoing clinical trials across multiple indications, including desmoid tumors and familial adenomatous polyposis. The company plans to start a Phase 3 registrational trial in desmoid tumors in the first half of 2027. Parabilis has not generated product revenue to date and reported a net loss of approximately $153 million for the 12 months ended March 31, 2026.